BACKGROUND: Screening decreases colorectal cancer (CRC) morbidity and mortality, yet remains underutilized. Screening breakdowns arise from lack of uptake and failure to follow-up after a positive screening test. OBJECTIVES: Systems of support to increase colorectal cancer screening and follow-up (SOS) is a randomized trial designed to increase: (1) CRC screening and (2) follow-up of positive screening tests. The Chronic Care Model and the Preventive Health Model inform study design. METHODS: The setting is a large nonprofit healthcare organization. In part-1 study, patients age 50-75 due for CRC screening are randomized to one of 4 study conditions. Arm 1 receives usual care. Arm 2 receives automated support (mailed information about screening choices and fecal occult blood tests (FOBT)). Arm 3 receives automated and assisted support (a medical assistant telephone call). Arm 4 receives automated, assisted, and care management support (a registered nurse provides behavioral activation and coordination of care). In part-2, study patients with a positive FOBT or adenomas on flexible sigmoidoscopy are randomized to receive either usual care or nurse care management. Primary outcomes are: 1) the proportion with CRC screening, 2) the proportion with a complete diagnostic evaluation after a positive screening test. RESULTS: We sent recruitment letters to 15,414 patients and 4675 were randomized. Randomly assigned treatment groups were similar in age, sex, race, education, self-reported health, and CRC screening history. CONCLUSIONS: We will determine the effectiveness and cost effectiveness of stepped increases in systems of support to increase CRC screening and follow-up after a positive screening test over 2years.
RCT Entities:
BACKGROUND: Screening decreases colorectal cancer (CRC) morbidity and mortality, yet remains underutilized. Screening breakdowns arise from lack of uptake and failure to follow-up after a positive screening test. OBJECTIVES: Systems of support to increase colorectal cancer screening and follow-up (SOS) is a randomized trial designed to increase: (1) CRC screening and (2) follow-up of positive screening tests. The Chronic Care Model and the Preventive Health Model inform study design. METHODS: The setting is a large nonprofit healthcare organization. In part-1 study, patients age 50-75 due for CRC screening are randomized to one of 4 study conditions. Arm 1 receives usual care. Arm 2 receives automated support (mailed information about screening choices and fecal occult blood tests (FOBT)). Arm 3 receives automated and assisted support (a medical assistant telephone call). Arm 4 receives automated, assisted, and care management support (a registered nurse provides behavioral activation and coordination of care). In part-2, study patients with a positive FOBT or adenomas on flexible sigmoidoscopy are randomized to receive either usual care or nurse care management. Primary outcomes are: 1) the proportion with CRC screening, 2) the proportion with a complete diagnostic evaluation after a positive screening test. RESULTS: We sent recruitment letters to 15,414 patients and 4675 were randomized. Randomly assigned treatment groups were similar in age, sex, race, education, self-reported health, and CRC screening history. CONCLUSIONS: We will determine the effectiveness and cost effectiveness of stepped increases in systems of support to increase CRC screening and follow-up after a positive screening test over 2years.
Authors: David M Mosen; Adrianne C Feldstein; Nancy Perrin; A Gabriela Rosales; David H Smith; Elizabeth G Liles; Jennifer L Schneider; Jennifer E Lafata; Ronald E Myers; Michael Kositch; Thomas Hickey; Russell E Glasgow Journal: Med Care Date: 2010-07 Impact factor: 2.983
Authors: James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby Journal: J Natl Cancer Inst Date: 2007-09-25 Impact factor: 13.506
Authors: Beverly B Green; Andy Bogart; Jessica Chubak; Sally W Vernon; Leo S Morales; Richard T Meenan; Sharon S Laing; Sharon Fuller; Cynthia Ko; Ching-Yun Wang Journal: Am J Prev Med Date: 2012-04 Impact factor: 5.043
Authors: Richard T Meenan; Melissa L Anderson; Jessica Chubak; Sally W Vernon; Sharon Fuller; Ching-Yun Wang; Beverly B Green Journal: Am J Prev Med Date: 2015-06 Impact factor: 5.043
Authors: Beverly B Green; Melissa L Anderson; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon Journal: Cancer Date: 2015-10-21 Impact factor: 6.860
Authors: Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon Journal: Cancer Date: 2017-07-28 Impact factor: 6.860
Authors: Caitlin C Murphy; Sally W Vernon; Nicole M Haddock; Melissa L Anderson; Jessica Chubak; Beverly B Green Journal: Prev Med Date: 2014-06-15 Impact factor: 4.018
Authors: Beverly B Green; Melissa L Anderson; Jessica Chubak; Laura Mae Baldwin; Leah Tuzzio; Sheryl Catz; Alison Cole; Sally W Vernon Journal: J Am Board Fam Med Date: 2016 Mar-Apr Impact factor: 2.657
Authors: Rachel L Winer; Jasmin A Tiro; Diana L Miglioretti; Chris Thayer; Tara Beatty; John Lin; Hongyuan Gao; Kilian Kimbel; Diana S M Buist Journal: Contemp Clin Trials Date: 2017-11-04 Impact factor: 2.226
Authors: Terry C Davis; Connie L Arnold; Charles L Bennett; Michael S Wolf; Cristalyn Reynolds; Dachao Liu; Alfred Rademaker Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-11-05 Impact factor: 4.254